1. Home
  2. YETI vs WVE Comparison

YETI vs WVE Comparison

Compare YETI & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo YETI Holdings Inc.

YETI

YETI Holdings Inc.

HOLD

Current Price

$47.53

Market Cap

3.3B

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$13.47

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YETI
WVE
Founded
2006
2012
Country
United States
Singapore
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
3.0B
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
YETI
WVE
Price
$47.53
$13.47
Analyst Decision
Buy
Strong Buy
Analyst Count
13
16
Target Price
$41.92
$29.94
AVG Volume (30 Days)
1.6M
3.9M
Earning Date
02-12-2026
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.93
N/A
Revenue
$1,831,326,000.00
$109,230,000.00
Revenue This Year
$4.00
N/A
Revenue Next Year
$5.47
$16.20
P/E Ratio
$24.63
N/A
Revenue Growth
1.56
103.75
52 Week Low
$26.61
$5.28
52 Week High
$51.29
$21.73

Technical Indicators

Market Signals
Indicator
YETI
WVE
Relative Strength Index (RSI) 53.84 44.47
Support Level $47.84 $13.22
Resistance Level $49.76 $14.51
Average True Range (ATR) 1.76 1.33
MACD -0.27 -0.37
Stochastic Oscillator 41.33 6.37

Price Performance

Historical Comparison
YETI
WVE

About YETI YETI Holdings Inc.

YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: